AdreView Product Monograph
... Long-term animal studies and studies in humans have not been conducted to evaluate AdreView’s carcinogenic potential or potential effects on fertility. Special Populations Pregnant Women: All female patients of reproductive age should be questioned on the possibility of being pregnant. A pregnancy t ...
... Long-term animal studies and studies in humans have not been conducted to evaluate AdreView’s carcinogenic potential or potential effects on fertility. Special Populations Pregnant Women: All female patients of reproductive age should be questioned on the possibility of being pregnant. A pregnancy t ...
oral bromfenac 10 and 25 mg compared with
... have examined the dose-response for sublingual buprenorphine. In one such comparison of sublingual buprenorphine 0.2, 0.4 and 0.8 mg with i.m. morphine 4,8 and 16 mg, a significant dose-response for sublingual buprenorphine was found, with a potency ratio to morphine of 1:15 [12]. Oral bromfenac pro ...
... have examined the dose-response for sublingual buprenorphine. In one such comparison of sublingual buprenorphine 0.2, 0.4 and 0.8 mg with i.m. morphine 4,8 and 16 mg, a significant dose-response for sublingual buprenorphine was found, with a potency ratio to morphine of 1:15 [12]. Oral bromfenac pro ...
Nonsteroidal anti-inflammatory drugs and their effects in the elderly
... Altered mechanisms of drug metabolism may prolong exposure to the harmful end products of the Cox pathways. Most analgesic doses are not adjusted for age; therefore, the most prudent way to prescribe these medications is to start at the lowest dose and titrate up as needed for effect. In patients wi ...
... Altered mechanisms of drug metabolism may prolong exposure to the harmful end products of the Cox pathways. Most analgesic doses are not adjusted for age; therefore, the most prudent way to prescribe these medications is to start at the lowest dose and titrate up as needed for effect. In patients wi ...
product monograph - Novo Nordisk Canada
... As an adjunct to diet and exercise to lower the blood glucose in patients with type 2 diabetes mellitus whose hyperglycemia cannot be controlled satisfactorily by diet and exercise alone. In combination therapy with metformin to lower blood glucose in patients whose hyperglycemia cannot be contr ...
... As an adjunct to diet and exercise to lower the blood glucose in patients with type 2 diabetes mellitus whose hyperglycemia cannot be controlled satisfactorily by diet and exercise alone. In combination therapy with metformin to lower blood glucose in patients whose hyperglycemia cannot be contr ...
Low Molecular Weight Heparin and Warfarin or Rivaroxaban for the
... Patients who are already on warfarin and well controlled, and who have not had adverse events. This is due to the lack of long-term safety data in this indication. History of gastrointestinal bleed Pregnancy or lactation Patients with cancer Patients with known antiphospholipid syndrome ...
... Patients who are already on warfarin and well controlled, and who have not had adverse events. This is due to the lack of long-term safety data in this indication. History of gastrointestinal bleed Pregnancy or lactation Patients with cancer Patients with known antiphospholipid syndrome ...
Drug/Application
... does not produce toxic metabolite and is slightly more active against aerobic gram (-) bacilli and less active against gram (+) ...
... does not produce toxic metabolite and is slightly more active against aerobic gram (-) bacilli and less active against gram (+) ...
Pharmacokinetics: Monitoring Aminoglycoside and Vancomycin
... primarily reported in patients with vancomycin concentrations > 80 mg/L. • As a single agent, vancomycin is associated with a low incidence of nephrotoxicity; however, when it is combined with aminoglycoside, the incidence may be as high as 30%. Winter ME. Basic Clinical Pharmacokinetics. 5th ed. Ph ...
... primarily reported in patients with vancomycin concentrations > 80 mg/L. • As a single agent, vancomycin is associated with a low incidence of nephrotoxicity; however, when it is combined with aminoglycoside, the incidence may be as high as 30%. Winter ME. Basic Clinical Pharmacokinetics. 5th ed. Ph ...
Prescribing Information
... a small number of cases. Because these changes are a marker for potential serious hepatotoxicity, serum aminotransferase levels must be measured prior to initiation of treatment and then monthly [see Dosage and Administration (2.2), Warnings and Precautions (5.1)]. In the postmarketing period, in th ...
... a small number of cases. Because these changes are a marker for potential serious hepatotoxicity, serum aminotransferase levels must be measured prior to initiation of treatment and then monthly [see Dosage and Administration (2.2), Warnings and Precautions (5.1)]. In the postmarketing period, in th ...
VAGINAL BLEEDING AFTER USE OF SINGLE DOSE ORAL
... Misoprostol is a synthetic prostaglandin-E1 analogue. It can be used in both gastroenterological and gynecological conditions. In gastroenterologic use, misoprostol therapy indicated in patients who have duodenal or gastric ulcer due to use nonsteroidal anti-inflammatory drugs (NSAIDs). It acts upon ...
... Misoprostol is a synthetic prostaglandin-E1 analogue. It can be used in both gastroenterological and gynecological conditions. In gastroenterologic use, misoprostol therapy indicated in patients who have duodenal or gastric ulcer due to use nonsteroidal anti-inflammatory drugs (NSAIDs). It acts upon ...
Nasalox Insert
... skip the missed dose and go back to regular dosing schedule. Do not take double doses. Contraindications Contraindicated in patients with hypersensivity to Oxymetazoline Hydrochloride. Side Effects When this medicine is used for short period of time at low doses, side effects are usually rare. Howev ...
... skip the missed dose and go back to regular dosing schedule. Do not take double doses. Contraindications Contraindicated in patients with hypersensivity to Oxymetazoline Hydrochloride. Side Effects When this medicine is used for short period of time at low doses, side effects are usually rare. Howev ...
Antifungal Agents - University of Minnesota
... New azoles, liposomal amphotericin New antifungals and formulations Altered fungal pathogenicity Changes in antifungal susceptibility testing ...
... New azoles, liposomal amphotericin New antifungals and formulations Altered fungal pathogenicity Changes in antifungal susceptibility testing ...
The Investigation of the Mupirocin effect on Epistaxis treatment in
... angiofibromanaso pharynx, and cavernous portion of the internal carotid artery can also cause the repeated epistaxis. Some systemic diseases such as hypertension, blood dyspraxia or any interference in clotting factors or platelet function makes patient prone to epistaxis (9). In treatment of epista ...
... angiofibromanaso pharynx, and cavernous portion of the internal carotid artery can also cause the repeated epistaxis. Some systemic diseases such as hypertension, blood dyspraxia or any interference in clotting factors or platelet function makes patient prone to epistaxis (9). In treatment of epista ...
package insert
... safe in a second rat study when administered around parturition and during lactation where the no adverse effect level for dam and pups was 210 mg/kg/day. There are no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human respo ...
... safe in a second rat study when administered around parturition and during lactation where the no adverse effect level for dam and pups was 210 mg/kg/day. There are no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human respo ...
Herbal Medicine for the Family Physician
... 1500 mg glucosamine sulfate or hydrochloride per day Likely safe in usual doses up to 3 years Likely effective for osteoarthritis symptoms after 4 weeks, comparable to NSAIDs, may prevent further deterioration In the lab glucosamine stimulates metabolism of chondrocytes in the articular cartilage an ...
... 1500 mg glucosamine sulfate or hydrochloride per day Likely safe in usual doses up to 3 years Likely effective for osteoarthritis symptoms after 4 weeks, comparable to NSAIDs, may prevent further deterioration In the lab glucosamine stimulates metabolism of chondrocytes in the articular cartilage an ...
ECX Regimen - Cancer Care Ontario
... clinical trial relevant to the Canadian context OR (where phase III trials are not feasible) an appropriately sized phase II trial. Regimens where one or more drugs are not approved by Health Canada for any indication will be identified under Rationale and Use. ...
... clinical trial relevant to the Canadian context OR (where phase III trials are not feasible) an appropriately sized phase II trial. Regimens where one or more drugs are not approved by Health Canada for any indication will be identified under Rationale and Use. ...
HEPATOPROTECTIVE ACTIVITY OF AN ETHANOLIC EXTRACT OF STEMS OF ANISOCHILUS CARNOSUS AGAINST CARBON TETRACHLORIDE INDUCED HEPATOTOXICITY IN RATS
... namely SGPT, SGOT, ALP and Total Bilirubin as shown in Group II of Table 1. ...
... namely SGPT, SGOT, ALP and Total Bilirubin as shown in Group II of Table 1. ...
teveten-hct
... approximately 13%. Eprosartan plasma concentrations peak at 1 to 2 hours after an oral dose in the fasted state. Administering eprosartan with food delays absorption, and causes variable changes (<25%) in Cmax and AUC values which do not appear clinically important. Plasma concentrations of eprosart ...
... approximately 13%. Eprosartan plasma concentrations peak at 1 to 2 hours after an oral dose in the fasted state. Administering eprosartan with food delays absorption, and causes variable changes (<25%) in Cmax and AUC values which do not appear clinically important. Plasma concentrations of eprosart ...
Review: Side Effects of Some Commonly Used Allergy Medications
... appear to be well tolerated. Drug metabolism occurs via the Cytochrome P450 system in liver, creating the potential for interactions with other medications using the P450 system; however, no such drug interactions have been reported to the FDA [15] Rare, but serious side effects of Montelukast have ...
... appear to be well tolerated. Drug metabolism occurs via the Cytochrome P450 system in liver, creating the potential for interactions with other medications using the P450 system; however, no such drug interactions have been reported to the FDA [15] Rare, but serious side effects of Montelukast have ...
Anticoagulant Dosing Management
... Laboratory testing: PT/INR prolonged; PTT prolonged at higher concentrations; Changes in PT/PTT small at therapeutic doses and variable; Anti-Xa accurate if proper standard is used Non-Urgent: Hold further doses of Apixaban For at least 24 hours before surgery or procedures for a low risk of bleed ...
... Laboratory testing: PT/INR prolonged; PTT prolonged at higher concentrations; Changes in PT/PTT small at therapeutic doses and variable; Anti-Xa accurate if proper standard is used Non-Urgent: Hold further doses of Apixaban For at least 24 hours before surgery or procedures for a low risk of bleed ...
sedation and analgesia in the icu
... • Effects are mediated by depressing the excitability of the limbic system via reversible binding at GABA receptor complex ...
... • Effects are mediated by depressing the excitability of the limbic system via reversible binding at GABA receptor complex ...
IBS
... 1. ↑gastric emptying and enhance small and large bowel transit (no effect on esophagus) 2. ↑ stool liquidity Mechanism of action of tegaserod: Serotonin 5HT₄ partial agonist. Binding to 5HT₄ receptors on the terminals of the 2nd order enteric neuron →↑ release of Ach and CGRP → ↑gastric emptying and ...
... 1. ↑gastric emptying and enhance small and large bowel transit (no effect on esophagus) 2. ↑ stool liquidity Mechanism of action of tegaserod: Serotonin 5HT₄ partial agonist. Binding to 5HT₄ receptors on the terminals of the 2nd order enteric neuron →↑ release of Ach and CGRP → ↑gastric emptying and ...
Protocol for Monoamine oxidase inhibitors (MAOIs) management
... Urinary alkalinization is not routinely recommended. Initial treatment should be directed towards controlling acute metabolic disturbances such as hyperkalemia, hyperthermia, and hypovolemia. Control seizures, agitation, and muscle contractions. Vigorous fluid replacement with 0.9% saline is necessa ...
... Urinary alkalinization is not routinely recommended. Initial treatment should be directed towards controlling acute metabolic disturbances such as hyperkalemia, hyperthermia, and hypovolemia. Control seizures, agitation, and muscle contractions. Vigorous fluid replacement with 0.9% saline is necessa ...
capecitabine - Cancer Care Ontario
... characterized by numbness, dysesthesia or paresthesia, tingling, painless or painful swelling, erythema, desquamation, blistering, and severe pain of the hands and/or feet and is more common in patients also receiving docetaxel. The median time to onset was 79 days. Dosage interruption/adjustment is ...
... characterized by numbness, dysesthesia or paresthesia, tingling, painless or painful swelling, erythema, desquamation, blistering, and severe pain of the hands and/or feet and is more common in patients also receiving docetaxel. The median time to onset was 79 days. Dosage interruption/adjustment is ...
Considerations when Undergoing Treatment for Chronic Illnesses
... Antibiotic Therapy and Herbal Therapy for Chronic Infections Subsets of fatiguing illnesses, GWI (~40-45%), FMS (60-70%), CFS (50-60%), autoimmune diseases (RA, MS, SLE, etc. ~50%) and neurological diseases (ALS, Parkinson’s, Alzheimer’s) show high incidence of chronic infections, such as Mycoplasma ...
... Antibiotic Therapy and Herbal Therapy for Chronic Infections Subsets of fatiguing illnesses, GWI (~40-45%), FMS (60-70%), CFS (50-60%), autoimmune diseases (RA, MS, SLE, etc. ~50%) and neurological diseases (ALS, Parkinson’s, Alzheimer’s) show high incidence of chronic infections, such as Mycoplasma ...
Dydrogesterone
Dydrogesterone (INN, USAN, BAN), is also chemically known as 9β,10α-pregna-4,6-diene-3,20-dione. Dydrogesterone (6-dehydro-retroprogesterone) is a hormonally active, non-androgenic steroid that was developed in the 1950s.Dydrogesterone has selective progestational activity and does not inhibit ovulation. The greater rigidity of dydrogesterone also positively affects its selectivity, while natural progesterone is less selective, existing in different conformations that more easily bind to different receptors. As a consequence of its better bioavailability and the progestational activity of its main metabolites (20-, 21- and 16-hydroxy derivatives), the equivalent dose of dydrogesterone is 10–20 times lower than that of oral micronized progesterone.Dydrogesterone is used as an effective, orally active progestogen for gynaecological conditions related to a wide variety of progesterone deficiencies in pregnant women. The molecular structure and pharmacological effects are somewhat similar to endogenous progesterone, although in smaller amounts it is found to be orally active. Its freedom from hormonal effects like those related to corticoid, androgenic, estrogenic, anabolic, and other effects gives dydrogesterone an advantage over other synthesized progestogens.Dydrogesterone when used therapeutically is closely related to its physiological action on the neuro-endocrine control of ovarian function, as well as on the endometrium. This is an indication in all cases of endogeneous progesterone deficiency - relative or absolute. The molecule was licensed for use in several indications, including threatened or recurrent miscarriage, dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhoea, irregular cycles, pre-menstrual syndrome and also as a hormone replacement therapy.Dydrogesterone has proven effective in the following conditions associated with progesterone deficiency: Infertility due to luteal insufficiency Threatened miscarriage Habitual or recurrent miscarriage. Menstrual disorders Premenstrual syndrome Endometriosis Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counter-check the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone acetate.